查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2005002

正子断层扫描（PET）市场：按产品类型、应用、最终用户和技术分類的全球市场预测，2026-2032年

Positron Emission Tomography Market by Product Type, Application, End User, Technology - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，正子断层扫描 (PET) 市场价值将达到 29.2 亿美元，到 2026 年将成长至 31.2 亿美元，到 2032 年将达到 45.7 亿美元，复合年增长率为 6.61%。

主要市场统计数据
基准年 2025 29.2亿美元
预计年份：2026年 31.2亿美元
预测年份 2032 45.7亿美元
复合年增长率 (%) 6.61%

全面概述正子断层扫描（PET）作为多维度成像技术，如何影响医疗领域的临床决策和策略投资。

正子断层扫描（PET）是现代分子影像的基石，它能够提供独特的视角，深入了解支撑诊断、治疗计划和治疗监测的生理和代谢过程。 PET 的应用使其不再只是一种诊断手段，而是一项引领精准医疗的综合技术，它整合了先进的硬体、放射化学和软体主导的分析。检测器设计、影像重建演算法和放射性示踪剂化学的进步，使其临床效用从肿瘤学扩展到神经病学、心臟病学以及其他新的适应症，从而重塑了诊疗路径和研究重点。

探讨技术、临床和商业性因素的整合如何加速 PET 能力的发展，扩大示踪剂组合，并重塑服务模式。

正子断层扫描（PET）领域正经历一场变革性的转变，这场转变正在重新定义临床实践、技术发展和经营模式。从类比检测器系统到全数位化、飞行时间（TOF）平台的过渡，提高了灵敏度、空间解析度和定量精度，从而缩短了扫描时间并减少了放射性示踪剂的剂量，同时又不影响诊断的可靠性。同时，放射化学的进步拓展了可用示踪剂的种类，使其不再局限于氟代脱氧葡萄糖，而是涵盖了淀粉样蛋白、 Tau蛋白、前列腺特异性抗原（PSA）和其他分子标靶靶向药物，从而开闢了新的临床途径。

对 2025 年前的累积关税调整如何重塑 PET 设备采购、示踪剂生产经济和跨境供应链策略进行分析评估。

到了2025年，美国实施的一系列关税措施的累积影响已对PET供应链、采购週期和跨境合作产生复杂的后果。影响进口扫描器组件、检测器材料和配件的关税调整增加了某些硬体配置的到货成本，迫使采购团队重新评估总拥有成本（TCO）并探索替代筹资策略。此外，用于放射性示踪剂製造的化学品和原材料的关税正在影响集中式和分散式示踪剂製造的成本结构，进而影响企业对自建迴旋加速器和区域生产网路的投资决策。

详细的细分洞察揭示了产品选择、临床应用、最终用户需求和技术水准如何结合起来决定 PET 的实施和营运策略。

要了解PET的发展趋势，需要仔细考虑产品、应用、最终用户和技术等各个维度如何相互作用，进而影响市场需求和临床效用。从产品类型来看，设备和放射性示踪剂发挥互补作用。专用PET扫描仪和PET/CT扫描仪决定了影像和处理能力，而FDG等放射性示踪剂则决定了诊断特异性和临床工作流程。在设备选择方面，通常需要在PET/CT系统提供的高通量和整合的解剖资讯与专用PET平台提供的特殊灵敏度和检查室最佳化之间进行权衡。放射性追踪剂的可用性和物流方面的考量因素，决定了影像中心网路中首选的临床适应症。

区域分析揭示了美洲、欧洲、中东和非洲以及亚太地区的基础设施、报销方案和研究重点如何影响PET的取得和策略机会。

PET部署和容量分布的区域趋势反映了美洲、欧洲、中东和非洲以及亚太地区医疗基础设施、报销框架和研究重点的差异。在美洲，完善的三级医疗网路和整合的肿瘤临床路径使得PET部署集中在都市区，同时私人诊断实验室和大学医院也积极参与其中。报销模式和临床指引的采纳影响着肿瘤和神经病学等适应症的优先顺序，而与放射化学中心的接近性则影响着示踪剂的可用性和当日检测的可行性。

本文重点介绍了硬体创新、放射化学优势、软体整合和服务模式如何决定 PET 的策略优势，并探讨了公司之间的竞争与合作趋势。

PET生态系中各公司之间的竞争格局取决于技术差异化、放射化学能力、整合服务交付以及拓展临床应用范围的策略伙伴关係。硬体供应商专注于检测器创新、与CT和MRI系统的互通性以及能够减少停机时间并优化扫描仪利用率的全生命週期服务模式。同时，放射性示踪剂生产商和放射性药物药局则在示踪剂种类、生产可靠性和物流效率方面展开竞争，尤其是在短寿命同位素领域，因为时间和配送网络对临床操作至关重要。设备供应商和示踪剂供应商之间的合作日益普遍，从而能够提供捆绑式解决方案，简化医疗机构的采购和营运整合。

为领导者提供切实可行的策略建议，以优化对 PET 的技术投资，确保示踪剂供应，增强分析能力，并提高营运韧性。

产业领导者若想充分利用PET日益增长的临床意义，应采取一套平衡的策略措施，涵盖技术选择、营运韧性和相关人员协作等面向。首先，将资本规划与临床优先事项结合，可确保设备投资与肿瘤科、神经科和心臟科所需的处理能力和诊断范围相符。领导者应评估数位PET和飞行时间（TOF）技术是否能提供足够的临床和工作流程优势，从而证明在高运作中心部署的合理性，同时保留适用于低运作环境的成本效益高的模拟方案。其次，透过本地生产伙伴关係或管理供应协议实现放射性示踪剂供应多元化，将降低营运风险，并支持整个转诊网路的一致服务。

采用透明且多方面的调查方法，结合专家访谈、技术文献整合和监管比较分析，以确保获得可靠的见解。

本报告的研究采用多方面方法，结合了定性专家对话和对技术文献、监管通知及临床指南趋势等第二手资料的整合。一手资讯来源包括对临床医生、医学物理学家、放射化学家、医疗系统采购经理和技术部门主管的结构化访谈，揭示了技术应用的驱动因素、营运限制和创新重点。二级资讯来源包括同行评审文章、会议论文集、监管出版刊物和示踪剂的专业书籍，记录了检测器技术、放射性示踪剂化学和图像分析技术的进步。

将技术进步、示踪剂扩展和策略倡议与 PET 在所有医疗环境中的永续临床应用联繫起来，从而实现明确的整合。

这份执行概要强调，由于技术日趋成熟、示踪剂种类不断丰富以及服务模式不断演进，PET正处于一个转折点。这些因素共同推动了PET在临床应用领域的拓展，同时也增加了其操作的复杂性。硬体能力、放射化学物流、软体驱动的分析以及政策环境之间的相互作用，将继续影响PET在所有医疗机构的部署模式。透过策略性地加强示踪剂供应多元化、有针对性地采用新技术以及投资于分析和人才培养，医疗机构能够在控製成本和营运风险的同时，充分发挥PET的临床潜力。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 正子断层扫描（PET）市场：依产品类型划分

  • 装置
    • 专用PET扫描仪
    • PET/CT扫描仪
  • 放射性示踪剂

第九章 正子断层扫描（PET）市场：依应用领域划分

  • 循环系统
  • 神经病学
  • 肿瘤学

第十章 正子断层扫描（PET）市场：依最终用户划分

  • 诊断中心
  • 医院
  • 研究机构

第十一章 正子断层扫描（PET）市场：依技术分类

  • 模拟PET
  • 数字PET
  • 飞行时间PET

第十二章 正子断层扫描（PET）市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 正子断层扫描（PET）市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 正子断层扫描（PET）市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国正子断层扫描（PET）市场

第十六章：中国正子断层扫描（PET）市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced Accelerator Applications
  • Canon Medical Systems Corporation
  • Cardinal Health, Inc.
  • Curium Pharma
  • General Electric Company
  • IBA Worldwide
  • Jubilant DraxImage Inc.
  • Koninklijke Philips NV
  • Lantheus Medical Imaging, Inc.
  • Mediso Medical Imaging Systems Kft.
  • Molecure SA
  • Neusoft Medical Systems Co., Ltd.
  • Nordion Inc.
  • Positron Corporation
  • Samsung Electronics Co., Ltd.
  • Siemens Healthineers AG
  • Sofie Biosciences, Inc.
  • United Imaging Healthcare Co., Ltd.
  • Yangzhou Kindsway Biotech Co., Ltd.
Product Code: MRR-742BD5183E5A

The Positron Emission Tomography Market was valued at USD 2.92 billion in 2025 and is projected to grow to USD 3.12 billion in 2026, with a CAGR of 6.61%, reaching USD 4.57 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.92 billion
Estimated Year [2026] USD 3.12 billion
Forecast Year [2032] USD 4.57 billion
CAGR (%) 6.61%

A comprehensive orientation to positron emission tomography as a multi-dimensional imaging modality shaping clinical decision-making and strategic investment across healthcare

Positron emission tomography represents a cornerstone of contemporary molecular imaging, delivering unique insights into physiological and metabolic processes that underpin diagnosis, treatment planning, and therapeutic monitoring. This introduction frames PET not merely as a diagnostic modality but as an integrative technology that converges hardware sophistication, radiochemistry, and software-driven analytics to inform precision medicine pathways. Advances in detector design, image reconstruction algorithms, and radiotracer chemistry have broadened clinical utility beyond oncology to neurology, cardiology, and emerging indications, thereby reshaping care pathways and research priorities.

As imaging departments and research institutes evaluate capital allocation and clinical workflows, PET's role in enabling targeted therapies and reducing diagnostic uncertainty has become increasingly salient. Concurrently, the ecosystem supporting PET has evolved to include service models for tracer supply, scanner-as-a-service offerings, and vendor partnerships that extend lifecycle support. This dynamic environment necessitates that stakeholders balance clinical value with operational complexity, supply chain resilience, and regulatory compliance. The following sections deploy a strategic lens to examine transformative shifts, policy impacts, segmentation-specific dynamics, regional variations, competitive behavior, and actionable recommendations that will guide healthcare providers, technology developers, and investors as they navigate the PET landscape.

An exploration of the converging technological, clinical, and commercial forces that are accelerating PET capability, expanding tracer portfolios, and reshaping service models

The PET landscape is undergoing transformative shifts that are redefining clinical practice, technology development, and commercial models. The transition from analog detector systems to fully digital and time-of-flight capable platforms has driven improvements in sensitivity, spatial resolution, and quantitative accuracy, enabling shorter acquisition times and reduced radiotracer dose without compromising diagnostic confidence. In parallel, advancements in radiochemistry have expanded the palette of available tracers beyond fluorodeoxyglucose to include agents targeting amyloid, tau, prostate-specific membrane antigen, and other molecular targets, thereby opening new clinical pathways.

Concurrently, software and artificial intelligence are layering additional value by automating image processing, enhancing lesion detection, and providing decision support that augments clinician workflows. These capabilities are increasingly integrated into vendor ecosystems, where post-processing and analytics become differentiators. Operationally, the landscape is shifting toward service-centric models, including managed tracer supply and remote system maintenance, which reduce capital barriers for smaller diagnostic centers and promote wider adoption. Regulatory harmonization and cross-border collaboration on tracer production are also evolving, with stakeholders navigating complex approval pathways to scale innovative agents. Taken together, these shifts create a more versatile and clinically potent PET environment while also raising new considerations related to access, reimbursement, and workforce readiness.

An analytical assessment of how cumulative tariff adjustments through 2025 have reshaped PET equipment sourcing, tracer production economics, and cross-border supply chain strategies

The cumulative effects of United States tariff measures enacted through 2025 have introduced a complex set of influences across PET supply chains, procurement cycles, and cross-border collaboration. Tariff adjustments that affect imported scanner components, detector materials, and accessory goods have increased landed costs for certain hardware configurations, prompting procurement teams to reassess total cost of ownership and to explore alternative sourcing strategies. In addition, tariffs on chemicals and raw materials used in radiotracer production have implications for the cost structure of centralized and decentralized tracer manufacturing, influencing decisions about in-house cyclotron investments and regional production networks.

Beyond direct cost implications, tariffs have affected strategic partnerships and vendor selection, as suppliers adjust manufacturing footprints and logistics networks to mitigate exposure. This has led some technology providers to diversify manufacturing locations and to strengthen local service capabilities in key markets to preserve competitive positioning. For clinical operations, increased costs can translate into extended equipment replacement cycles, prioritization of high-throughput clinical indications, and closer scrutiny of utilization metrics to justify capital expense. At the same time, regulatory and customs complexities introduced by tariff changes have accentuated the need for robust compliance and trade expertise within organizations that import critical components or that engage in cross-border clinical trials. In response, stakeholders are accelerating supply chain transparency initiatives, exploring nearshoring options, and engaging in collaborative purchasing arrangements to preserve access to advanced imaging capabilities under shifting trade conditions.

In-depth segmentation insights revealing how product choices, clinical applications, end-user needs, and technology tiers coalesce to determine PET adoption and operational strategy

Understanding PET dynamics requires close attention to how product, application, end user, and technology dimensions interact to shape demand and clinical utility. From a product type perspective, equipment and radiotracers serve complementary roles: dedicated PET scanners and PET/CT scanners define imaging capability and throughput, while radiotracers such as FDG determine diagnostic specificity and clinical workflows. Equipment decisions often trade off between the high throughput and integrated anatomical context provided by PET/CT systems and the specialized sensitivity and station optimization of dedicated PET platforms. Radiotracer availability and logistical considerations can dictate the clinical indications that are prioritized within a network of imaging sites.

Application segmentation reveals differing clinical drivers; cardiology prioritizes perfusion and viability assessments, neurology emphasizes neurodegenerative disease characterization and seizure localization, and oncology leverages PET for staging, therapy selection, and response assessment. These application needs translate into distinctive utilization patterns across end users: diagnostic centers focus on outpatient workflows and referral-driven imaging volumes, hospitals integrate PET into multidisciplinary care pathways and inpatient workups, and research institutes emphasize protocol flexibility and novel tracer evaluation. Technology choices intersect with these dynamics, as analog PET systems may be retained for cost-sensitive settings while digital PET and time-of-flight platforms are adopted where the clinical value of higher resolution and faster throughput justifies investment. Consequently, strategic planning must account for how product type, application, end user, and technology preferences collectively influence procurement, training, and service models across diverse care settings.

A regional analysis that maps how infrastructure, reimbursement, and research priorities in the Americas, Europe Middle East & Africa, and Asia-Pacific shape PET access and strategic opportunities

Regional dynamics in PET adoption and capability distribution reflect differences in healthcare infrastructure, reimbursement frameworks, and research emphasis that vary across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, well-developed tertiary care networks and integrated oncology pathways have supported concentrated PET deployment in urban centers, accompanied by strong involvement from private diagnostic providers and academic medical centers. Reimbursement models and clinical guideline adoption influence the prioritization of indications such as oncology and neurology, while proximity to radiochemistry hubs affects tracer availability and the viability of same-day assays.

Across Europe, Middle East & Africa, heterogeneous regulatory regimes and diverse healthcare financing models create a mosaic of PET access levels; several markets demonstrate advanced clinical integration supported by national reimbursement policies and established radiopharmacy networks, whereas others are constrained by logistical and capital limitations. In Asia-Pacific, rapid investment in healthcare infrastructure, expanding clinical trial activity, and growing incidence of oncology and neurodegenerative disease are driving the expansion of PET services, often supported by government-led initiatives and public-private partnerships that accelerate facility build-outs and tracer production. These regional differences have implications for equipment manufacturers, tracer suppliers, and service providers, each of which must tailor engagement strategies to local regulatory requirements, referral patterns, and channel structures to effectively support adoption and sustainable operations.

Competitive and collaborative company trends highlighting how hardware innovation, radiochemistry strength, software integration, and service models define strategic advantage in PET

Competitive dynamics among companies in the PET ecosystem are defined by technology differentiation, radiochemistry capabilities, integrated service offerings, and strategic partnerships that extend clinical reach. Hardware providers focus on detector innovation, interoperability with CT and MRI systems, and lifecycle service models that reduce downtime and optimize scanner utilization. At the same time, radiotracer manufacturers and radiopharmacies compete on tracer variety, production reliability, and logistics performance, particularly for short-lived isotopes where timing and distribution networks are critical to clinical operations. Collaborative arrangements between equipment vendors and tracer suppliers are increasingly common, enabling bundled solutions that simplify procurement and operational integration for healthcare providers.

Companies are also innovating in software, adding quantification tools and AI-driven workflows that improve throughput and standardize reporting. Service providers offering managed supply or scanner-as-a-service models are expanding their footprint to lower barriers for smaller centers. Strategic alliances with academic centers and participation in multicenter trials help firms validate new tracers and technologies, accelerating clinical acceptance. For buyers, these dynamics mean evaluating partners not only on product specifications but also on the strength of service networks, regulatory expertise, and the ability to support clinical validation and reimbursement pathways. As the ecosystem matures, competitive advantage increasingly accrues to organizations that can offer end-to-end solutions encompassing hardware, tracer supply, analytics, and sustained operational support.

A pragmatic set of strategic recommendations for leaders to optimize technology investments, secure tracer supply, enhance analytics, and strengthen operational resilience in PET

Industry leaders seeking to capitalize on PET's expanding clinical relevance should pursue a balanced set of strategic actions that address technology choices, operational resilience, and stakeholder engagement. First, aligning capital planning with clinical priorities ensures that equipment investments match the throughput and diagnostic breadth required by oncology, neurology, and cardiology services. Leaders should evaluate whether digital PET and time-of-flight technologies deliver sufficient clinical and workflow benefits to justify adoption in high-volume sites while maintaining cost-effective analog options for lower-volume settings. Second, securing radiotracer supply through diversified sourcing, local production partnerships, or managed supply agreements reduces operational risk and supports consistent service delivery across referral networks.

Third, investing in software and analytics that streamline image processing, reporting, and data integration will enhance clinician adoption and enable value demonstration to payers. Fourth, implementing rigorous supply chain transparency and trade compliance practices will mitigate the operational impacts of tariff and policy changes. Fifth, fostering collaborative relationships with academic centers, clinical trial consortia, and payer stakeholders can accelerate evidence generation needed for guideline inclusion and reimbursement. Finally, building workforce competencies through targeted training for technologists, physicists, and interpreting physicians ensures that organizations can extract the full clinical value of advanced PET capabilities. These recommendations, taken together, create a pragmatic roadmap for organizations to expand PET services in a sustainable and clinically impactful way.

A transparent multi-method research methodology combining expert interviews, technical literature synthesis, and regulatory comparative analysis to ensure robust insights

The research underlying this report integrates a multi-method approach that combines qualitative expert engagement with secondary synthesis of technical literature, regulatory filings, and clinical guideline developments. Primary inputs include structured interviews with clinicians, medical physicists, radiochemists, health system procurement leaders, and technology executives to surface adoption drivers, operational constraints, and innovation priorities. Secondary sources encompass peer-reviewed publications, conference proceedings, regulatory agency publications, and tracer monographs that document advances in detector technology, radiotracer chemistry, and image analysis techniques.

Analytical steps involved thematic synthesis of qualitative inputs, technology capability mapping, and cross-regional regulatory comparison to elucidate adoption patterns and strategic considerations. Attention was given to validation through triangulation across practitioner interviews, technical documentation, and published clinical evidence. Care was taken to ensure factual accuracy by referencing up-to-date regulatory guidance and peer-reviewed findings on tracer performance and detector characteristics. Ethical considerations and data provenance were observed in primary data collection, with interview subjects engaged under agreed confidentiality terms. The methodology emphasizes transparency and reproducibility, enabling decision-makers to understand the evidence base that informs the insights and recommendations presented in the report.

A conclusive synthesis that connects technological progress, tracer expansion, and strategic action to the sustainable clinical integration of PET across care settings

This executive synthesis underscores that PET is at an inflection point driven by technological refinement, broader tracer portfolios, and evolving service models that together expand clinical applications and operational complexity. The interplay between hardware capability, radiochemistry logistics, software-enabled analytics, and policy environments will continue to shape adoption patterns across care settings. Strategic responses that emphasize diversified tracer supply, targeted technology deployment, and investment in analytics and workforce development will enable providers to realize PET's clinical promise while managing cost and operational risk.

Stakeholders who integrate evidence-generation activities, such as participation in multicenter trials and local validation studies, will be better positioned to influence guideline adoption and reimbursement decisions. Furthermore, proactive supply chain and trade compliance strategies can mitigate disruption stemming from tariff and policy shifts. Ultimately, the organizations that succeed will be those that combine clinical leadership with operational agility and collaborative partnerships, translating PET's technical advances into sustainable improvements in patient care and research capability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Positron Emission Tomography Market, by Product Type

  • 8.1. Equipment
    • 8.1.1. Dedicated Pet Scanners
    • 8.1.2. Pet/Ct Scanners
  • 8.2. Radiotracers

9. Positron Emission Tomography Market, by Application

  • 9.1. Cardiology
  • 9.2. Neurology
  • 9.3. Oncology

10. Positron Emission Tomography Market, by End User

  • 10.1. Diagnostic Centers
  • 10.2. Hospitals
  • 10.3. Research Institutes

11. Positron Emission Tomography Market, by Technology

  • 11.1. Analog Pet
  • 11.2. Digital Pet
  • 11.3. Time-Of-Flight Pet

12. Positron Emission Tomography Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Positron Emission Tomography Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Positron Emission Tomography Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Positron Emission Tomography Market

16. China Positron Emission Tomography Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Advanced Accelerator Applications
  • 17.6. Canon Medical Systems Corporation
  • 17.7. Cardinal Health, Inc.
  • 17.8. Curium Pharma
  • 17.9. General Electric Company
  • 17.10. IBA Worldwide
  • 17.11. Jubilant DraxImage Inc.
  • 17.12. Koninklijke Philips N.V.
  • 17.13. Lantheus Medical Imaging, Inc.
  • 17.14. Mediso Medical Imaging Systems Kft.
  • 17.15. Molecure S.A.
  • 17.16. Neusoft Medical Systems Co., Ltd.
  • 17.17. Nordion Inc.
  • 17.18. Positron Corporation
  • 17.19. Samsung Electronics Co., Ltd.
  • 17.20. Siemens Healthineers AG
  • 17.21. Sofie Biosciences, Inc.
  • 17.22. United Imaging Healthcare Co., Ltd.
  • 17.23. Yangzhou Kindsway Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DEDICATED PET SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DEDICATED PET SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DEDICATED PET SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PET/CT SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PET/CT SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PET/CT SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RADIOTRACERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RADIOTRACERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RADIOTRACERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ANALOG PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ANALOG PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY ANALOG PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIGITAL PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY DIGITAL PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TIME-OF-FLIGHT PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TIME-OF-FLIGHT PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TIME-OF-FLIGHT PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 105. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 123. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 129. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)